Notice: This company has been marked as potentially delisted and may not be actively trading. Interpace Biosciences (IDXG) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesTrends IDXG vs. NEO, VCYT, LH, DGX, DVA, CHE, CRVL, RCM, AMED, and MDShould you be buying Interpace Biosciences stock or one of its competitors? The main competitors of Interpace Biosciences include NeoGenomics (NEO), Veracyte (VCYT), Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Chemed (CHE), CorVel (CRVL), R1 RCM (RCM), Amedisys (AMED), and Pediatrix Medical Group (MD). Interpace Biosciences vs. NeoGenomics Veracyte Laboratory Co. of America Quest Diagnostics DaVita Chemed CorVel R1 RCM Amedisys Pediatrix Medical Group Interpace Biosciences (NASDAQ:IDXG) and NeoGenomics (NASDAQ:NEO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership, community ranking and media sentiment. Which has stronger earnings & valuation, IDXG or NEO? Interpace Biosciences has higher earnings, but lower revenue than NeoGenomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterpace Biosciences$40.21M0.29$800KN/AN/ANeoGenomics$591.64M3.36-$87.97M-$0.61-25.36 Do institutionals & insiders have more ownership in IDXG or NEO? 5.7% of Interpace Biosciences shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 5.5% of Interpace Biosciences shares are held by company insiders. Comparatively, 1.3% of NeoGenomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer IDXG or NEO? NeoGenomics has a consensus price target of $20.25, indicating a potential upside of 30.90%. Given NeoGenomics' stronger consensus rating and higher possible upside, analysts plainly believe NeoGenomics is more favorable than Interpace Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Interpace Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeoGenomics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor IDXG or NEO? In the previous week, NeoGenomics had 5 more articles in the media than Interpace Biosciences. MarketBeat recorded 5 mentions for NeoGenomics and 0 mentions for Interpace Biosciences. NeoGenomics' average media sentiment score of 0.31 beat Interpace Biosciences' score of 0.00 indicating that NeoGenomics is being referred to more favorably in the news media. Company Overall Sentiment Interpace Biosciences Neutral NeoGenomics Neutral Is IDXG or NEO more profitable? Interpace Biosciences has a net margin of 10.39% compared to NeoGenomics' net margin of -12.07%. NeoGenomics' return on equity of -2.11% beat Interpace Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Interpace Biosciences10.39% -8.09% 37.14% NeoGenomics -12.07%-2.11%-1.18% Does the MarketBeat Community favor IDXG or NEO? NeoGenomics received 183 more outperform votes than Interpace Biosciences when rated by MarketBeat users. However, 72.83% of users gave Interpace Biosciences an outperform vote while only 70.90% of users gave NeoGenomics an outperform vote. CompanyUnderperformOutperformInterpace BiosciencesOutperform Votes31972.83% Underperform Votes11927.17% NeoGenomicsOutperform Votes50270.90% Underperform Votes20629.10% Which has more volatility & risk, IDXG or NEO? Interpace Biosciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, NeoGenomics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. SummaryNeoGenomics beats Interpace Biosciences on 11 of the 16 factors compared between the two stocks. Ad Insiders Exposed917 Trades… Zero Losses?As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”Go here to see how you can start accessing these opportunities today Get Interpace Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IDXG vs. The Competition Export to ExcelMetricInterpace BiosciencesSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.79M$4.48B$5.10B$8.84BDividend YieldN/A36.79%5.04%4.07%P/E RatioN/A14.3295.1214.22Price / Sales0.2944.111,217.3088.42Price / Cash4.2352.2739.4936.27Price / Book-0.205.836.976.37Net Income$800,000.00$13.76M$118.73M$225.56M Interpace Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IDXGInterpace BiosciencesN/A$2.68+0.4%N/A+135.6%$11.79M$40.21M0.00152Gap DownNEONeoGenomics3.4202 of 5 stars$15.47+0.7%$20.25+30.9%-21.3%$1.99B$591.64M-25.182,100VCYTVeracyte4.1416 of 5 stars$39.31+0.3%$41.25+4.9%+50.5%$3.05B$361.05M-261.33790Analyst ForecastLHLaboratory Co. of America4.7778 of 5 stars$239.58+0.7%$255.92+6.8%+12.7%$20.04B$12.71B46.0167,000Positive NewsDGXQuest Diagnostics4.9045 of 5 stars$163.59+1.4%$164.58+0.6%+19.7%$18.26B$9.25B21.6948,000Analyst DowngradeDVADaVita4.3779 of 5 stars$163.96+1.6%$161.80-1.3%+65.5%$13.44B$12.14B17.4170,000Positive NewsCHEChemed4.9051 of 5 stars$560.78+1.4%$641.50+14.4%-4.5%$8.44B$2.26B27.9815,087Ex-DividendPositive NewsCRVLCorVel1.4267 of 5 stars$357.01+0.5%N/A+66.0%$6.12B$795.31M75.424,870Positive NewsRCMR1 RCM3.1492 of 5 stars$14.31flat$15.41+7.7%N/A$6.04B$2.25B0.0030,000News CoverageAMEDAmedisys3.9891 of 5 stars$90.04+0.0%$100.67+11.8%-4.1%$2.95B$2.24B35.7119,000MDPediatrix Medical Group3.5872 of 5 stars$14.66+1.2%$16.10+9.8%+61.0%$1.26B$1.99B0.005,170Analyst ForecastNews Coverage Related Companies and Tools Related Companies NeoGenomics Competitors Veracyte Competitors Laboratory Co. of America Competitors Quest Diagnostics Competitors DaVita Competitors Chemed Competitors CorVel Competitors R1 RCM Competitors Amedisys Competitors Pediatrix Medical Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IDXG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Interpace Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Interpace Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
